Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
ConclusionsPerioperative DOS improved MPR significantly and tended to produce longer PFS compared to SOX in LAG/GEJ cancer in Asia, and might be considered as a preferred option for perioperative chemotherapy and worth further investigation.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Eloxatin | Esophagus Cancer | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Study | Taxotere